| scholarly article | Q13442814 |
| P50 | author | Blaise A Clarke | Q60683603 |
| Michelle Letarte | Q87551907 | ||
| Tomer Feigenberg | Q92197996 | ||
| Alexandra Kollara | Q96195020 | ||
| Theodore J. Brown | Q46857872 | ||
| P2093 | author name string | Barry Rosen | |
| Carl Virtanen | |||
| Marcus Q Bernardini | |||
| Anna Plotkin | |||
| K Joan Murphy | |||
| P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. | Q50764794 | ||
| Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. | Q51962005 | ||
| VEGF Trap for the treatment of malignant ascites. | Q54541279 | ||
| A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer | Q56743807 | ||
| Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss | Q61626110 | ||
| Ascites as a predictor of ovarian malignancy | Q78618360 | ||
| The Origin of Ovarian Cancer — Is It Getting Clearer? | Q85187684 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis | Q26851836 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome | Q33359495 | ||
| Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. | Q34081282 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Identification of prognostic factors in advanced epithelial ovarian carcinoma | Q34344858 | ||
| Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer | Q34396474 | ||
| TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models | Q34694524 | ||
| Modeling high-grade serous ovarian carcinogenesis from the fallopian tube | Q34938333 | ||
| Immunity and immune suppression in human ovarian cancer | Q35138135 | ||
| HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma | Q36184723 | ||
| Worldwide burden of gynaecological cancer: the size of the problem | Q36344510 | ||
| Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. | Q36358324 | ||
| Palliation of malignant ascites | Q36418452 | ||
| Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. | Q36796557 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. | Q38498880 | ||
| HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. | Q40465429 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma | Q46390942 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 367103 | |
| P577 | publication date | 2014-05-25 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites | |
| P478 | volume | 2014 |
| Q48559871 | An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer |
| Q41557623 | Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. |
| Q35921404 | Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? |
| Q48345561 | Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks |
| Q38997171 | Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy |
| Q35575822 | MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma |
| Q64892975 | Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role? |
| Q90475913 | STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer |
| Q38896754 | The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis |
Search more.